Literature DB >> 7572814

Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay.

D A Hendricks1, B J Stowe, B S Hoo, J Kolberg, B D Irvine, P D Neuwald, M S Urdea, R P Perrillo.   

Abstract

The aim of this study was to establish the performance characteristics of a nonradioisotopic branched DNA (bDNA) signal amplification assay for quantitation of hepatitis B virus (HBV) DNA in human serum. Quantitation was determined from a standard curve and expressed as HBV DNA equivalents/mL (Eq/mL; 285,000 Eq = 1 pg of double stranded HBV DNA). The bDNA assay exhibited a nearly four log dynamic range of quantitation and an analytical detection limit of approximately 100,000 Eq/mL. To ensure a specificity of 99.7%, the quantitation limit was set at 700,000 Eq/mL. The interassay percent coefficient of variance for quantification values ranged from 10% to 15% when performed by novice users with different sets of reagents. Using the bDNA assay, HBV DNA was detected in 94% to 100% of hepatitis B e antigen-positive specimens and 27% to 31% of hepatitis B e antigen-negative specimens from chronic HBV-infected patients. The bDNA assay may be useful as a prognostic and therapy monitoring tool for the management of HBV-infected patients undergoing antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572814     DOI: 10.1093/ajcp/104.5.537

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  29 in total

Review 1.  Strategies for signal amplification in nucleic acid detection.

Authors:  S C Andras; J B Power; E C Cocking; M R Davey
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  Evaluation of the COBAS TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA.

Authors:  Rafael M Gordillo; Juan Gutiérrez; Manuel Casal
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Authors:  M L Collins; B Irvine; D Tyner; E Fine; C Zayati; C Chang; T Horn; D Ahle; J Detmer; L P Shen; J Kolberg; S Bushnell; M S Urdea; D D Ho
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

4.  Regulation of insulin preRNA splicing by glucose.

Authors:  J Wang; L Shen; H Najafi; J Kolberg; F M Matschinsky; M Urdea; M German
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

5.  Comparative evaluation of semiautomated COBAS AMPLICOR hepatitis B virus (HBV) monitor test and manual microwell plate-based AMPLICOR HBV MONITOR test.

Authors:  I J Marin; M Poljak; K Seme; J Meglic-Volkar; M Maticic; G Lesnicar; V Brinovec
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay.

Authors:  M Krajden; L Comanor; O Rifkin; A Grigoriew; J M Minor; G F Kapke
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  Detection of hepatitis B virus DNA in sera from patients with chronic hepatitis B virus infection by DNA microarray method.

Authors:  Kazunori Kawaguchi; Shuichi Kaneko; Masao Honda; Hiroshi F Kawai; Yukihiro Shirota; Kenichi Kobayashi
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

8.  Nucleic acid capture assay, a new method for direct quantitation of nucleic acids.

Authors:  Siao Ping Tsai; Anne Wong; Elaine Mai; Pamela Chan; Grace Mausisa; Mark Vasser; Parkash Jhurani; Mogens H Jakobsen; Wai Lee T Wong; Jean-Philippe Stephan
Journal:  Nucleic Acids Res       Date:  2003-03-15       Impact factor: 16.971

9.  New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

10.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.